News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
704,885 Results
Type
Article (40044)
Company Profile (250)
Press Release (664590)
Multimedia
Podcasts (59)
Webinars (14)
Section
Business (204295)
Career Advice (2011)
Deals (35461)
Drug Delivery (95)
Drug Development (81151)
Employer Resources (172)
FDA (16252)
Job Trends (14887)
News (345533)
Policy (32613)
Tag
Academia (2556)
Accelerated approval (9)
Adcomms (22)
Allergies (95)
Alliances (49579)
ALS (108)
Alzheimer's disease (1441)
Antibody-drug conjugate (ADC) (155)
Approvals (16249)
Artificial intelligence (310)
Autoimmune disease (28)
Automation (18)
Bankruptcy (361)
Best Places to Work (11636)
BIOSECURE Act (19)
Biosimilars (122)
Biotechnology (175)
Bladder cancer (94)
Brain cancer (33)
Breast cancer (365)
Cancer (2864)
Cardiovascular disease (212)
Career advice (1682)
Career pathing (30)
CAR-T (185)
CDC (30)
Cell therapy (498)
Cervical cancer (22)
Clinical research (66859)
Collaboration (1012)
Company closure (3)
Compensation (686)
Complete response letters (22)
COVID-19 (2625)
CRISPR (56)
C-suite (325)
Cystic fibrosis (112)
Data (2991)
Decentralized trials (2)
Denatured (20)
Depression (60)
Diabetes (346)
Diagnostics (6423)
Digital health (23)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (138)
Drug pricing (121)
Drug shortages (28)
Duchenne muscular dystrophy (124)
Earnings (87456)
Editorial (40)
Employer branding (21)
Employer resources (148)
Events (113742)
Executive appointments (845)
FDA (17898)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (929)
Gene editing (129)
Generative AI (22)
Gene therapy (373)
GLP-1 (781)
Government (4501)
Grass and pollen (4)
Guidances (181)
Healthcare (18840)
HIV (40)
Huntington's disease (30)
IgA nephropathy (39)
Immunology and inflammation (146)
Immuno-oncology (8)
Indications (39)
Infectious disease (2797)
Inflammatory bowel disease (148)
Inflation Reduction Act (10)
Influenza (62)
Intellectual property (119)
Interviews (312)
IPO (16591)
IRA (44)
Job creations (3637)
Job search strategy (1424)
Kidney cancer (13)
Labor market (52)
Layoffs (492)
Leadership (19)
Legal (7932)
Liver cancer (79)
Longevity (11)
Lung cancer (399)
Lymphoma (208)
Machine learning (11)
Management (58)
Manufacturing (384)
MASH (90)
Medical device (13462)
Medtech (13467)
Mergers & acquisitions (19588)
Metabolic disorders (847)
Multiple sclerosis (97)
NASH (16)
Neurodegenerative disease (113)
Neuropsychiatric disorders (32)
Neuroscience (2116)
NextGen: Class of 2025 (6517)
Non-profit (4488)
Now hiring (47)
Obesity (427)
Opinion (218)
Ovarian cancer (102)
Pain (105)
Pancreatic cancer (120)
Parkinson's disease (186)
Partnered (22)
Patents (298)
Patient recruitment (164)
Peanut (50)
People (57685)
Pharmaceutical (63)
Pharmacy benefit managers (21)
Phase I (20829)
Phase II (29448)
Phase III (21923)
Pipeline (1628)
Policy (199)
Postmarket research (2563)
Preclinical (8870)
Press Release (64)
Prostate cancer (140)
Psychedelics (36)
Radiopharmaceuticals (253)
Rare diseases (457)
Real estate (5917)
Recruiting (66)
Regulatory (22630)
Reports (50)
Research institute (2326)
Resumes & cover letters (350)
Rett syndrome (9)
RNA editing (8)
RSV (49)
Schizophrenia (86)
Series A (157)
Series B (108)
Service/supplier (11)
Sickle cell disease (60)
Special edition (18)
Spinal muscular atrophy (148)
Sponsored (32)
Startups (3588)
State (2)
Stomach cancer (14)
Supply chain (76)
Tariffs (57)
The Weekly (37)
Vaccines (778)
Venture capital (54)
Weight loss (256)
Women's health (47)
Worklife (16)
Date
Today (56)
Last 7 days (357)
Last 30 days (1867)
Last 365 days (31220)
2025 (16748)
2024 (35231)
2023 (40093)
2022 (51178)
2021 (55710)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (720)
Alabama (61)
Alaska (7)
Arizona (243)
Arkansas (13)
Asia (38208)
Australia (6232)
California (7432)
Canada (2358)
China (670)
Colorado (320)
Connecticut (318)
Delaware (192)
Europe (82104)
Florida (1116)
Georgia (247)
Hawaii (1)
Idaho (59)
Illinois (637)
India (27)
Indiana (361)
Iowa (16)
Japan (227)
Kansas (108)
Kentucky (29)
Louisiana (14)
Maine (64)
Maryland (1021)
Massachusetts (5522)
Michigan (246)
Minnesota (449)
Mississippi (3)
Missouri (90)
Montana (28)
Nebraska (25)
Nevada (80)
New Hampshire (66)
New Jersey (2072)
New Mexico (28)
New York (2083)
North Carolina (1079)
North Dakota (8)
Northern California (3272)
Ohio (235)
Oklahoma (16)
Oregon (34)
Pennsylvania (1610)
Puerto Rico (17)
Rhode Island (36)
South America (1098)
South Carolina (34)
South Dakota (1)
Southern California (2780)
Tennessee (126)
Texas (1123)
United States (27534)
Utah (219)
Virginia (184)
Washington D.C. (72)
Washington State (631)
West Virginia (4)
Wisconsin (66)
704,885 Results for "seagen inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Policy
Arbitration Dispute Between Daiichi Sankyo and Seagen Ends
A dispute between Daiichi Sankyo Co., Ltd. (TSE: 4568) and Seagen Inc. is now concluded and Seagen has paid Daiichi Sankyo approximately U.S. $47 million in connection with attorneys’ fees and costs plus interest awarded by the arbitrator of the party’s dispute.
June 28, 2024
·
1 min read
Earnings
Pfizer Announces Another $1.7B in Cost Savings, Including R&D Revamp
Pfizer’s R&D organization has been in flux for almost two years now, since the $43 billion acquisition of ADC specialist Seagen. The new cuts were revealed in the company’s Q1 earnings report.
April 29, 2025
·
2 min read
·
Annalee Armstrong
Deals
Pfizer Completes Acquisition of Seagen
Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Seagen Inc. (NASDAQ: SGEN), a global biotechnology company that discovers, develops and commercializes transformative cancer medicines.
December 14, 2023
·
8 min read
Patents
Daiichi Sankyo Wins $47M in ADC Patent Arbitration With Seagen, Pfizer Dispute Looms
Daiichi Sankyo has secured a victory in its patent arbitration with Seagen, nabbing a $47 million award for attorneys’ fees and other costs, plus interest. However, a larger patent battle with Pfizer remains.
July 1, 2024
·
2 min read
·
Tristan Manalac
Policy
Daiichi Sankyo Wins $47M in ADC Patent Arbitration With Seagen, Pfizer Dispute Looms
Daiichi Sankyo has secured a victory in its patent arbitration with Seagen, nabbing a $47 million award for attorneys’ fees and other costs, plus interest. However, a larger patent battle with Pfizer remains.
July 1, 2024
·
2 min read
·
Tristan Manalac
Drug Development
Pfizer’s $43B Seagen Buy Starts to Pay Off with Adcetris Phase III Data in DLBCL
Antibody-drug conjugate Adcetris, when used with rituximab or lenalidomide, improved overall survival in patients with relapsed or refractory diffuse large B-cell lymphoma. Pfizer secured access to Seagen’s ADC in March 2023.
March 12, 2024
·
2 min read
·
Tristan Manalac
Deals
Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen
Pfizer Inc. (NYSE: PFE) today announces that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, expired December 11, 2023, with respect to Pfizer’s pending acquisition of Seagen Inc.
December 12, 2023
·
9 min read
Business
Seagen Third Quarter 2023 Financial Results Reflect Strong Product Sales Growth, and Significant Portfolio and Pipeline Progress
Seagen Inc. (Nasdaq:SGEN) (Seagen or the Company) reported financial results today for the third quarter ended September 30, 2023.
November 1, 2023
·
20 min read
Business
Seagen to Report Third Quarter 2023 Financial Results on November 1, 2023
Seagen Inc. (Nasdaq: SGEN) announced today that it will report third quarter 2023 financial results on Wednesday, November 1, 2023.
October 12, 2023
·
1 min read
Deals
Seagen Stockholders Approve Acquisition by Pfizer
Following a special meeting of its stockholders, Seagen Inc. (Nasdaq: SGEN) today announced that its stockholders voted to approve a proposal to adopt the previously announced merger agreement under which Pfizer will acquire Seagen for $229 per share in cash.
May 30, 2023
·
4 min read
1 of 70,489
Next
